Interleukin-10, Transforming Growth Factor-beta, Interleukin-17, and Tumor Necrosis Factor-alpha (IL-10, TGF-β, IL-17, TNF-α)

These *inflammatory cytokines* are small, secreted proteins that modulate immune functions. IL-10 is an anti-inflammatory cytokine involved in suppressing immune cell activation and excessive inflammatory responses[4]. TGF-β has dual roles, both promoting regulatory T cell differentiation and, with other signals, driving differentiation of pro-inflammatory Th17 cells[3]. IL-17 is a highly pro-inflammatory cytokine produced by Th17 cells and several innate lymphocytes, driving both protective immunity and immunopathology in autoimmunity by promoting neutrophil recruitment, antimicrobial responses, and inflammatory gene expression[2][5]. TNF-α, produced by T cells, macrophages, and innate cells, is central to inflammatory diseases and acts through its receptors to skew immune responses towards pathogenic phenotypes, being implicated in various chronic diseases[1]. Drugs targeting these cytokines (especially TNF-α, IL-17, and TGF-β) are approved for clinical use in autoimmune and inflammatory diseases, but modulation can have significant safety challenges such as increased infection risk and unwanted suppression of protective immunity[5][4][6]. Note: The target entry as provided is not the standard scientific style; each cytokine should be listed as a distinct therapeutic target with its own attributes.

Other names

IL-10 (CSIF—cytokine synthesis inhibitory factor)TGF-beta (Transforming Growth Factor beta, TGF-β1)IL-17 (Interleukin-17, often refers specifically to IL-17A; Th17 cytokine)TNF-alpha (Tumor Necrosis Factor alpha, TNF)

Neutralization of cytokine with monoclonal antibodies (e.g. anti-TNF, anti-IL-17) Inhibition of cytokine receptor signaling Reduction of downstream inflammatory gene expression